Promote the development of vaccines with high development priorities and accelerate discussions on NIP vaccination
Committee:
Vaccinesstatus:
Progress
It is noted in the draft revision of the next Basic Plan: "In order to expedite the study of NIP, we will start collecting and organizing the necessary information after development and before regulatory approval and consider making it possible to request the preparation of a Factsheet promptly after regulatory approval. In addition, we will consider regulatory measures such as PMDA consultation to support early practical application." It is an achievement that the next Basic Plan includes the early consideration of NIP of necessary vaccines, which has been continuously advocated in the "Incentivize Vaccines with High Development Priority" by 4 Dantai, including EFPIA Japan VWT. In addition, MHLW is currently selecting the next high-priority vaccine for development in accordance with the revised Basic Plan, and it is necessary to monitor it. Herpes zoster vaccines, high-dose influenza vaccines, and RSV vaccines have already been selected from EFPIA Japan member companies.
Recommendations
- Improving the predictability of NIP is being incorporated into the government's basic policy, and we will promote the creation of clear criteria for NIP and the creation of a system that allows discussions on NIP to begin even before the vaccine is approved. In addition, the financial impact of NIP is touched upon in the next Basic Plan, and EFPIA Japan will propose the creation of an environment in which Japan citizens are protected from preventable diseases regardless of financial barriers.